Curcumin improved liposomal mitomycin-induced cell toxicity in bladder cancer cell

Document Type : Research Paper


1 Department of Drug and Food Control, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

2 Targeted Drug Delivery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical science, Mashhad, Iran

4 Nanotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran


Objective (s): This study aimed at investigation of preparation and stability study of Mitomycin and Mitomycin loaded nanoliposems and efficacy of the combination of Mitomycin -loaded nanoliposomes and Curcumin versus Mitomycin in suppressing HTB-9 and L929 cell lines, in vitro.
Materials and Methods: An HPLC method was validated based on Q2 (R1) International Conference on Harmonization (ICH) guideline for determination of Mitomycin in pharmaceutical samples. Soybean phosphatidylcholine (SPC) or hydrogenated soybean phosphatidylcholine (HSPC) mixed with cholesterol at 2:1 molar ratio respectively in two different groups to prepare Mitomycin nanoliposomes. Cell toxicity of free Mitomycin, Mitomycin loaded liposomes and curcumin was measured using MTT assay in bladder cancer cell line for treatment group and Fibroblast-like cell as control group. Also, propidium iodide staining was done to determine the level of DNA fragmentation.
Results: The validated HPLC method showed stability based on the ICH guideline (n=3 and RSD<2%). Encapsulation efficiency values were 78 and 63 % for SPC and HSPC liposomes, respectively. Sizes of SPC and HSPC liposomes were 112 and 128 nm, respectively. Encapsulation efficiency of Mitomycin was 27 and 21 % for SPC and HSPC liposomes, respectively. Addition of Curcumin to the samples remarkably improved Mitomycin cytotoxicity. Concerning DNA fragmentation, Curcumin exhibited a protective effect when used in combination with Mitomycin.
Conclusion: Synergistic effects of Curcumin and Mitomycin were observed in terms of cell toxicity. Together, since Curcumin exerts anti-oxidative properties, its co-administration with a chemotherapeutic agent might protect normal cells from adverse effects of such drugs.


1. Tomasz M. Mitomycin C: small, fast and deadly (but very selective). J Chem Biol. 1995; 2(9): 575-579.
2. Friedrich MG, Pichlmeier U, Schwaibold H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette–Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol. 2007; 52(4): 1123–1129.
3. Zargar H, Aning J, Ischia J. Optimizing intravesical Mitomycin C therapy in non-muscle-invasive bladder cancer. Nat Rev Urol. 2014; 11(4): 220–230.
4. Au JL, Badalament RA, Wientjes MG. Methods to improve efficacy of intravesical Mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001; 93(8): 597–604.
5. Wientjes MG, Badalament RA, Au JL. Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical Mitomycin C therapy for superficial bladder cancer. Cancer Chemother Pharmacol. 1993; 32(4): 255–262.
6. Quebbeman EJ, Hoffman NE, Ausman RK, Hamid AA. Stability of Mitomycin admixtures. Am J Hosp Pharm. 1985; 42(8):1750-1754
7. Jolck R.I., Feldborg L.N, Andersen S, Moghimi SM, Andresen TL. Engineering liposomes and nanoparticles for biological targeting. J. Adv. Biochem. Eng Biotechnol. 2011; 125(5): 251-280.
8. Re F, Cambianica I, Sesana S, Salvati E, Cagnotto A, Salmona M. Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloidbeta peptide. J Biotechnol. 2011; 156(4): 341-346.
9. Yang H. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. J Pharm Res. 2010; 27(9): 1759-71.
10. Sharma OP. Antioxidant activity of Curcumin and related compounds. Biochem Pharmacol. 1976; 25(15): 1811–1812.
11. Herr HW, Laudone VP, Whitmore WF. An overview of intravesical therapy for superficial bladder tumors. J Urol. 1987; 138(6): 1363–1368.
12. Ruby AJ, Kuttan G, Babu K D, Rajasekharan KN, Kuttan R. Anti-tumour and antioxidant activity of natural Curcumin oids. Cancer Lett. 1995; 94(1): 79–83.
13. Sugiyama Y, Kawakishi S, Osawa T. Involvement of the -diketone moiety in the antioxidative mechanism of tetrahydro Curcumin. Biochem Pharmacol. 1996; 52(6): 519–25.
14. Srimal RC, Dhawan BN. Pharmacology of diferuloyl methane (Curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol. 1973; 25(6): 447–452.
15. Jordan WC, Drew CR. Curcumin ––a natural herb with antiHIV activity. J Natl Med Assoc. 1996; 88(6): 333-338.
16. Mahady GB, Pendland SL, Yun G, Lu ZZ. Turmeric (Curcuma longa) and Curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen. Anticancer Res. 2002; 22(6C): 4179–4181.
17. Kim MK, Choi GJ, Lee HS. Fungicidal property of Curcuma longa L.rhizome-derived Curcumin against phytopathogenic fungi in a greenhouse. J Agric Food Chem. 2003; 51(6): 1578–1581.
18. Kuttan R, Bhanumathy P, Nirmala K, George MC. Potentialanticancer activity of turmeric (Curcuma longa). Cancer Lett. 1985 29(2): 197–202.
19. Kiso Y, Suzuki Y, Watanabe N, Oshima Y Hikino H. Antihepatotoxic principles of Curcuma longa rhizomes. Planta Med. 1983; 49(3): 185–187.
20. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of Curcumin (diferuloyl methane). Indian J Med Res. 1980; 71(1): 632–634.
21. Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE. Dose escalation of a Curcumin oid formulation. BMC. Complement. Altern Med. 2006; 6: 10-17.
22. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR ,Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY. Phase I clinical trial of Curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001; 21(4B): 2895–2900.
23. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. AdV Exp Med Biol. 2007; 595: 1–75.
24. Choudhuri T, Pal S, Agwarwal ML, Das T, Sa G. Curcumin induces apopto sis in human breast cancer cells through p53 dependent Bax induction.FEBS Lett. 2002; 512(1):334–340.
25. Benjamin N, Breyer M.D., Jared M, Whitson M.D., Peter R, Carroll M.D., Badrinath R, Konety M.D. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol. 2010; 28(5) 510-514.
26. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits prolif eration, invasion, angiogenesis and metastasis of diferent cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008; 269(2):199–225.
27. Lev-Ari S, Zinger H, Kazanov D, Yona D, Ben-Yosef R, Starr A, Figer A, Arber N. Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. J. Biomed. Pharmacother. 2005; 59(2): 276-280.
28. Zhou Qian Mei, Sun Yang, Lu Yi Yu, Zhang Hui, Chen Qi Long, Su Shi Bing. Curcumin reduces Mitomycin C resistance in breast cancer stem cells by regulating Bcl-2 family-mediated apoptosis. J cancer cell int. 2017; 84(3): 1-17.
29. Malik P, Ameta RK, Singh M. Preparation and characterization of bionanoemulsions for improving and modulating the antioxidant efficacy of natural phenolic antioxidant Curcumin. J Chem Biol Interact. 2014; 222(5): 77-86.
30. Yao M, Yang L, Wang J, Sun YL, Dun RL, Wang YJ, Cui XJ. Neurological recovery and antioxidant effects of Curcumin for spinal cord injury in the rat: a network meta-analysis and systematic review. J Neurotrauma. 2015; 32(6):381-392.
31. Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of Curcumin. J Adv Exp Med Biol. 2007; 595:105-125.
32. Qianmei Zhou, Meina Ye, Yiyu Lu, Hui Zhang, Qilong Chen, Shuang Huang, Shibing Su. Curcumin Improves the Tumoricidal Effect of Mitomycin C by Suppressing ABCG2 Expression in Stem Cell-Like Breast Cancer Cells. J Pone one. 2015; 10(6): 1-12.